| Autor: |
Messa GL; Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy., La Placa G; Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy., Puccetti L; Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy., Acciavatti A; Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy., Provvedi T; Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy., Palazzini E; Alfa Wassermann SpA, Bologna, Italy., Di Perri T; Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy. |
| Abstrakt: |
Twenty-four patients with vascular disorders, randomly divided into 3 dosage groups of 8 patients, were treated with a single oral dose of sulodexide (50, 100 or 200mg) and placebo. Tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1) activity and antigen, euglobulin lysis time, α2-antiplasmin, plasminogen, fibrinogen, blood and plasma viscosity, and whole blood filtration rate were determined before administration and over the following 24 hours. Sulodexide significantly increased t-PA activity linearly with the dose over the range of 50 to 200mg. At the same time, it also significantly decreased the concentration of PAI-1 linearly and proportionally with the dose. No clear effects were observed on the other monitored parameters, although euglobulin lysis time and plasma viscosity showed a tendency to decrease after the administration of sulodexide. These results justify the clinical activity of sulodexide. Indeed, the concomitant increase of t-PA and decrease of PAI-1 activity and antigen might increase the natural fibrinolytic activity with a physiological potentiation, without other adverse effects. The known activity of sulodexide in decreasing plasma viscosity during long term treatment is, however, not immediately explicable by the single-dose effects. |
Full text from SpringerLink